N-Terminal domain antiandrogen | |
---|---|
Drug class | |
![]() EPI-001, the first major N-terminal domain AR antagonist to be developed. | |
Class identifiers | |
Synonyms | N-Terminal domain AR antagonists; AR NTD antagonists |
Use | Prostate cancer |
Biological target | Androgen receptor |
Legal status | |
In Wikidata |
N-Terminal domain antiandrogens are a novel type of antiandrogen that bind to the N-terminal domain of the androgen receptor (AR) instead of the ligand-binding domain (where all currently-available antiandrogens bind) and disrupt interactions between the AR and its coregulatory binding partners, thereby blocking AR-mediated gene transcription. They are being investigated for the treatment of prostate cancer.
See also
[edit]References
[edit]ARTooltip Androgen receptor |
| ||||||
---|---|---|---|---|---|---|---|
GPRC6A |
| ||||||